

> d his

(FILE 'HOME' ENTERED AT 16:09:22 ON 31 MAR 2003)

FILE 'EUROPATFULL, PCTFULL, USPATFULL, USPAT2, WPIDS' ENTERED AT
16:09:51

ON 31 MAR 2003

E GRAHAM B/IN

L1 57 S E3-E12
L2 0 S L1 AND (VIRUS OR VIRAL)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:11:03 ON 31 MAR 2003

E GRAHAM B/AU

L3 465 S E3-E12
L4 73 S L3 AND (VIRUS OR VIRAL)
L5 0 S L4 AND HMG?
L6 0 S L4 AND (?STATIN)
L7 1498 S (?STATIN) (L) (VIRUS OR VIRAL)
L8 35 S L7 (L) HMG?
L9 12 S L8 NOT PY>=2000

FILE 'EUROPATFULL, PCTFULL, USPATFULL, USPAT2, WPIDS' ENTERED AT
16:18:24

ON 31 MAR 2003

L10 369 S L9
L11 2145 S (?STATIN) (S) (VIRUS OR VIRAL)
L12 0 S L11 (S) ((HMG(2W) COA) (4A) INHITIT?)
L13 42 S L11 (S) (HMG(2W) COA)
L14 10 S L13 NOT PY>=2000
L15 5131 S LOVASTATIN OR SIMVASTATIN OR FLUVASTATIN OR ATORVASTATIN OR
P
L16 146 S L15 (S) (VIRUS OR VIRAL)
L17 33 S L16 NOT PY>=2000
L18 15 S L16/CLM
L19 5 S L18 NOT PY>=2000

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:38:53 ON 31 MAR 2003

L20 935081 S 17
L21 47 S L17
L22 0 S L21 AND (RSV OR RESPIRATORY(W) SYNCYTIAL)
L23 7 S L16 AND (RSV OR RESPIRATORY(W) SYNCYTIAL)

FILE 'EUROPATFULL, PCTFULL, USPATFULL, USPAT2, WPIDS' ENTERED AT
16:46:21

ON 31 MAR 2003

=> s 23

L24 2943448 23

=> s 123

L25 8 L23

=> s ibib 1-8

L26 1 IBIB 1-8

=> d l25 ibib 1-8

L25 ANSWER 1 OF 8 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002069977 PCTFULL ED 20020926 EW 200237
TITLE (ENGLISH): USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL

TITLE (FRENCH): DEFICIENCIES
 TRAITEMENT DE DEFICIENCES AFFECTANT LES GLOBULES
 SANGUINS
 INVENTOR(S): AHLEM, Clarence, N., 8960 Montrose Way, San Diego, CA
 92122, US;
 READING, Christopher, P.O. Box 12511, San Diego, CA
 92122, US;
 FRINCKE, James, P.O. Box 927420, San Diego, CA 92192,
 US;
 STICKNEY, Dwight, 5275 Ashby Lane, Granite Bay, CA
 95746, US;
 LARDY, Henry, 1829 Thorstand Road, Madison, WI 53705,
 US;
 MARWAH, Padma, 6710 Spring Grove Court, Middleton, WI
 53562, US;
 MARWAH, Ashok, 6710 Spring Grove Court, Middleton, WI
 53562, US;
 PRENDERGAST, Patrick, T., Baybush, Straffan, County
 Kildare, IE
 PATENT ASSIGNEE(S): HOLLIS-EDEN PHARMACEUTICALS, INC., Suite 400, 4435
 Eastgate Mall, San Diego, CA 92121, US [US, US]
 AGENT: MUENCHAU, Daryl\$, Hollis-Eden Pharmaceuticals, Inc.,
 Suite 400, 4435 Eastgate Mall, San Diego, CA 92121\$,
 US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE

	WO 2002069977	A1	20020912
DESIGNATED STATES			
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW		
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-US6708	A	20020301
PRIORITY INFO.:	US 2001-60/272,624		20010301
	US 2001-09/820,483		20010329
	US 2001-60/323,016		20010910
	US 2001-60/328,738		20011011
	US 2001-60/340,054		20011101
	US 2001-60/338,015		20011108
	US 2001-60/343,523		20011220

=> s e1-e35

727 1068-55-9/BI
396 135371-29-8/BI
1805 13734-41-3/BI
60 149910-63-4/BI
2 158861-33-7/BI

13 160141-19-5/BI
13 160141-20-8/BI
12 160141-21-9/BI
5 160141-46-8/BI
5 160141-47-9/BI
5 160141-48-0/BI
5 160141-49-1/BI
3 169168-10-9/BI
1 169168-11-0/BI
1 169168-12-1/BI
2 169168-13-2/BI
2 169168-14-3/BI
4 169168-15-4/BI
4 169168-16-5/BI
1 169168-17-6/BI
1 169168-18-7/BI
1 169168-19-8/BI
1 169168-20-1/BI
1 169168-21-2/BI
1 169168-22-3/BI
1 169168-23-4/BI
1 169168-24-5/BI
1 169168-26-7/BI
2 169328-13-6/BI
3438 24424-99-5/BI
104 24629-25-2/BI
319 3017-69-4/BI
775 7517-19-3/BI

e9 →
e29

DETD . . . can be utilized to
create expression plasmids for a ras gene include, but are not limited
to, pCI, pSI, pSport (Promega), pBK-CMV, pBK-RSV (Stratagene),
pEUK-CI (Clontech), pCMV-LIC (Pharmingen) and
pcDNA1.1/Amp (Invitrogen).

13

Cell-based in vitro ras prenylation assay

The cell lines used in this assay consist of either Rat1 or
NIH3T3 cells transformed by either **viral** H-ras; an N-ras
chimeric gene

in which the C-terminal hypervariable region of v-H-ras was substituted
with the corresponding region from the N-ras gene; or ras-CVLL
(SEQ.ID.NO.: 1), a **viral**-H-ras mutant in which the C-terminal
exon

encodes leucine instead of serine, making the encoded protein a
substrate

for geranylgeranylation by GGPTase I. . . . ml methionine-free DMEM
supple-

mented with 10% regular DMEM, 2% fetal bovine serum, 400
gCi[35S]methionine (1000 Ci/mmol) and test compound(s). Cells
treated with **lovastatin**, a compound that blocks Ras processing
in

- 150 -

cells by inhibiting the rate-limiting step in the isoprenoid
biosynthetic
pathway (Hancock, J.F. . . .

L25 ANSWER 5 OF 8 PCTFULL COPYRIGHT 2003 Univentio

DETD Table;8
Gene Oncogene/Virus
m-Actin H-ras
Adeno
v-K-ras
SV40
E1A
myosin Heavy Chain E1A
Myosin Light Chain v-K-ras
a-Tropomyosin v-K-ras
v-H-ras
V-mos
v-fms
v-fes
v-src
SV40
RSV
MyoD1 H-ras
Myogenin TGFB
V-fos
Collagen V-mos
alDha2 (I) v-frc
v-ras
H-2K E1A
(class 1MHC) Adeno
Neu E1A
Phosphoenol pyruvate E1A
carboxykinase
Polyoma E1A

Examples of reporter units having regulatory regions that are activated. . .

2) Various temperature sensitive oncogenic proteins and **viruses** have been reported: SV40 T antigen (67); v-abl (68); p53 (69) & Ki-MSV (70). The establishment of tumors using these oncogene forms. . . be effective in reversing the transformed phenotype produced by these oncogenes as well as some human colon tumors (77, 78r 75), Similarly, **Lovastatin** which interferes with the posttranslational modification of the Ras precursor protein inhibits ras activation in mammalian cells (80).

L25 ANSWER 5 OF 8

ACCESSION NUMBER:

TITLE (ENGLISH):

TITLE (FRENCH):

INVENTOR(S):

PATENT ASSIGNEE(S):

LANGUAGE OF PUBL.:

DOCUMENT TYPE:

PATENT INFORMATION:

PCTFULL COPYRIGHT 2003 Univentio

1993023533 PCTFULL ED 20020513

ANTI-NEOPLASTIC IN VIVO DRUG SCREEN

TEST IN VIVO DE MEDICAMENTS ANTI-NEOPLASIQUES

LEIBOWITZ, Paul, J.;

WADSWORTH, Samuel;

WOON, Chee-Wai

TSI CORPORATION

English

Patent

NUMBER	KIND	DATE
--------	------	------

WO 9323533	A1	19931125
------------	----	----------

DESIGNATED STATES

W:

AU CA FI JP NO AT BE CH DE DK ES FR GB GR IE IT LU MC

NL PT SE

APPLICATION INFO.:

WO 1993-US4363	A	19930507
----------------	---	----------

PRIORITY INFO.:

US 1992-7/879,933		19920508
-------------------	--	----------

L25 ANSWER 4 OF 8 PCTFULL COPYRIGHT 2003 Univention
ACCESSION NUMBER: 1999010525 PCTFULL ED 20020515
TITLE (ENGLISH): A METHOD OF TREATING CANCER
TITLE (FRENCH): PROCÉDE POUR LE TRAITEMENT DU CANCER
INVENTOR(S): HEIMBROOK, David, C.;

PATENT ASSIGNEE(S) : DeFEO-JONES, Deborah;
OLIFF, Allen, I.;
STIRDIVANT, Steven, M.
MERCK & CO., INC.;
HEIMBROOK, David, C.;
DeFEO-JONES, Deborah;
OLIFF, Allen, I.;
STIRDIVANT, Steven, M.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9910525 A1 19990304

DESIGNATED STATES

W:

AL	AM	AU	AZ	BA	BB	BG	BR	BY	CA	CN	CU	CZ	EE	GE	HR	HU	ID
IL	IS	JP	KG	KR	KZ	LC	LK	LR	LT	LV	MD	MG	MK	MN	MX	NO	NZ
PL	RO	RU	SG	SI	SK	SL	TJ	TM	TR	TT	UA	US	UZ	VN	YU	GH	GM
KE	LS	ME	SD	SZ	UG	ZW	AM	AZ	BY	KG	KZ	MD	RU	TJ	TM	AT	BE
CH	CY	DE	DK	ES	FI	FR	GB	GR	IE	IT	LU	MC	NL	PT	SE	BF	BJ
CF	CG	CI	CM	GA	GN	GW	ML	MR	NE	SN	TD	TG					

APPLICATION INFO.:

PRIORITY INFO.:

WO 1998-US17699	A	19980826
US 1997-60/057,102		19970827
GB 1997-9724299.4		19971118

=> d his

(FILE 'HOME' ENTERED AT 16:09:22 ON 31 MAR 2003)

FILE 'EUROPATFULL, PCTFULL, USPATFULL, USPAT2, WPIDS' ENTERED AT
16:09:51

ON 31 MAR 2003

E GRAHAM B/IN

L1 57 S E3-E12

L2 0 S L1 AND (VIRUS OR VIRAL)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:11:03 ON 31 MAR 2003

E GRAHAM B/AU

L3 465 S E3-E12

L4 73 S L3 AND (VIRUS OR VIRAL)

L5 0 S L4 AND HMG?

L6 0 S L4 AND (?STATIN)

L7 1498 S (?STATIN) (L) (VIRUS OR VIRAL)

L8 35 S L7 (L) HMG?

L9 12 S L8 NOT PY>=2000

FILE 'EUROPATFULL, PCTFULL, USPATFULL, USPAT2, WPIDS' ENTERED AT
16:18:24

ON 31 MAR 2003

L10 369 S L9

L11 2145 S (?STATIN) (S) (VIRUS OR VIRAL)

L12 0 S L11 (S) ((HMG(2W) COA) (4A) INHITIT?)

L13 42 S L11 (S) (HMG(2W) COA)

L14 10 S L13 NOT PY>=2000

L15 5131 S LOVASTATIN OR SIMVASTATIN OR FLUVASTATIN OR ATORVASTATIN OR
P

L16 146 S L15 (S) (VIRUS OR VIRAL)

L17 33 S L16 NOT PY>=2000

L23 ANSWER 7 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 ACCESSION NUMBER: 2001:194941 BIOSIS
 DOCUMENT NUMBER: PREV200100194941
 TITLE: Antiviral activity of **lovastatin** against
 respiratory syncytial virus in
 vivo and in vitro.
 AUTHOR(S): Gower, Tara L.; Graham, Barney S. (1)
 CORPORATE SOURCE: (1) Vanderbilt University School of Medicine, 1161 21st
 Ave. South, A-4103 MCN, Nashville, TN, 37232-2582:
 bgraham@mail.nih.gov USA
 SOURCE: Antimicrobial Agents and Chemotherapy, (April, 2001) Vol.
 45, No. 4, pp. 1231-1237. print.
 ISSN: 0066-4804.
 DOCUMENT TYPE: Article
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 TI Antiviral activity of **lovastatin** against **respiratory**
 syncytial virus in vivo and in vitro.
 AB **Respiratory syncytial virus** (RSV)
 is an important human pathogen that can cause severe and life-threatening
 respiratory infections in infants and immunocompromised adults. We have
 recently shown that the RSV F glycoprotein, which mediates
 viral fusion, binds to RhoA. One of the steps in RhoA activation
 involves isoprenylation at the carboxy terminus of the protein. . .
 allows RhoA to be attached to phosphatidyl serine on the inner leaflet of
 the plasma membrane. Treatment of mice with **lovastatin**, a drug
 that inhibits prenylation pathways in the cell by directly inhibiting
 hydroxymethylglutaryl coenzyme A reductase, diminishes RSV but
 not vaccinia **virus** replication when administered up to 24 h
 after RSV infection and decreases **virus**-induced weight
 loss and illness in mice. The inhibition of replication is not likely due
 to the inhibition of cholesterol biosynthesis, since gemfibrozil, another
 cholesterol-lowering agent, did not affect **virus** replication and
 serum cholesterol levels were not significantly lowered by
 lovastatin within the time frame of the experiment.
 Lovastatin also reduces cell-to-cell fusion in cell culture and
 eliminates RSV replication in HEp-2 cells. These data indicate
 that **lovastatin**, more specific isoprenylation inhibitors, or
 other pharmacological approaches for preventing RhoA membrane
 localization
 should be considered for evaluation as a preventive antiviral therapy for
 selected groups of patients at high risk for severe RSV disease,
 such as the institutionalized elderly and bone marrow or lung transplant
 recipients.
 IT Major Concepts
 Infection; Pharmacology
 IT Diseases
 respiratory syncytial virus infection: viral
 disease
 IT Chemicals & Biochemicals
 F glycoprotein; RhoA; cholesterol; lovastatin: HMG CoA reductase
 inhibitor - drug, antiviral - drug
 IT Alternate Indexing
 Respiratory Syncytial Virus Infections (MeSH)
 ORGN . . .
 Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia;
 Paramyxoviridae: Animal Viruses, Viruses, Microorganisms
 ORGN Organism Name
 HEp-2 cell line (Hominidae); mouse (Muridae); **respiratory**

syncytial virus (Paramyxoviridae): pathogen

ORGN Organism Superterms

Animal Viruses; Animals; Chordates; Humans; Mammals; Microorganisms;
Nonhuman Mammals; Nonhuman Vertebrates; Primates; Rodents;
Vertebrates;. . .

ACCESSION NUMBER: 1999005161 PCTFULL ED 20020515
 TITLE (ENGLISH): HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
 (PPARγ) GENE REGULATORY SEQUENCES AND USES
 THEREFOR
 TITLE (FRENCH): SEQUENCES REGULATRICES DU GENE HUMAIN PPARγ
 (RECEPTEUR GAMMA ACTIVE DE LA PROLIFERATION DES
 PEROXYSOMES) ET LEURS UTILISATIONS
 INVENTOR(S): BRIGGS, Michael, R.;
 SALADIN, Regis, S.;
 AUWERX, Johan;
 FAJAS, Lluís
 PATENT ASSIGNEE(S): LIGAND PHARMACEUTICALS INCORPORATED;
 INSTITUT PASTEUR;
 BRIGGS, Michael, R.;
 SALADIN, Regis, S.;
 AUWERX, Johan;
 FAJAS, Lluís
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9905161	A1	19990204

DESIGNATED STATES
 W:

AL	AM	AT	AU	AZ	BA	BB	BG	BR	BY	CA	CH	CN	CU	CZ	DE	DK	EE
ES	FI	GB	GE	GH	GM	HR	HU	ID	IL	IS	JP	KE	KG	KP	KR	KZ	LC
LK	LR	LS	LT	LU	LV	MD	MG	MK	MN	MW	MX	NO	NZ	PL	PT	RO	RU
SD	SE	SG	SI	SK	SL	TJ	TM	TR	TT	UA	UG	US	UZ	VN	YU	ZW	GH
GM	KE	LS	MW	SD	SZ	UG	ZW	AM	AZ	BY	KG	KZ	MD	RU	TJ	TM	AT
BE	CH	CY	DE	DK	ES	FI	FR	GB	GR	IE	IT	LU	MC	NL	PT	SE	BF
BJ	CF	CG	CI	CM	GA	GN	GW	ML	MR	NE	SN	TD	TG				

APPLICATION INFO.: WO 1998-US15411 A 19980724
 PRIORITY INFO.: US 1997-60/053,692 19970725

4

4, 5, 6, 8.

cholesterol synthesis, provide another way to modify cellular cholesterol levels. Upon treatment, with compounds such as compactin or **simvastatin**, cells will become cholesterol depleted and the production of the active forms of ADD-1/SREBP-1 will increase (Sakai et al., Cell 85:1037-1046. . . . Therefore, the expression of PPAR γ protein was evaluated in Hep G2 cells before and after treatment with the potent HMG-CoA reductase inhibitor, **simvastatin**. Treatment of the cells with **simvastatin** (5 x 10⁻⁶ M) during 6 hours resulted in a robust and fast induction of PPAR γ protein levels (4-fold), which. . . .

Candidate PPAR γ Modulators

The following molecules and their derivatives and homologs are candidate PPAR γ modulators:

- (1) HMG-CoA reductase inhibitors, including, but not limited to, **simvastatin**, **atorvastatin**, **pravastatin**, and **fluvastatin**
- (2) Cholesterol and its metabolites such as the various oxysterols,
- (3) Insulin and insulin mimetics,
- (4) Glucocorticoid hormones, including, but not limited to, . . . including conditions involving skin (e.g., urticaria and eczema) and lungs (asthma), immunologic disorders (e.g., graft versus-host disease), parasitic infections, bacterial infections, and **viral** infections.

Because PPAR γ is highly expressed in cells involved in host defense, a modulator of PPAR γ expression can be used to enhance. . . .

L19 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1999004238 PCTFULL ED 20020515
 TITLE (ENGLISH): REAGENTS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF PROLIFERATIVE DISORDERS
 TITLE (FRENCH): REACTIFS, PROCES DE DIAGNOSTIC ET PRONOSTIC DE TROUBLES PROLIFERATIFS
 INVENTOR(S): PAGANO, Michele;
 DRAETTA, Giulio;
 ROLFE, Mark;
 LODA, Massimo
 PATENT ASSIGNEE(S): MITOTIX, INC.;
 DEACONESS HOSPITAL;
 PAGANO, Michele;
 DRAETTA, Giulio;
 ROLFE, Mark;
 LODA, Massimo
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9904238	A2	19990128

DESIGNATED STATES
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC

APPLICATION INFO.:
PRIORITY INFO.:

LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
WO 1998-US14566 A 19980714
US 1997-08/893,276 19970715